Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset. A combination of nivolumab and ipilimumab induced significant antitumor activity among men with metastatic castration-resistant prostate cancer and a positive immunogenic signature, according to results of the phase 2 NEPTUNES trial.
Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).
Nivolumab-ipilimumab combo demonstrated significant antitumor activity in PCA
Researchers presented the data at the virtual American Association for Cancer Research Annual Meeting. The NEPTUNES study has demonstrated a 29% response rate in patients with quite heavily pretreated metastatic prostate cancer. In patients with either mismatch repair deficiency or BRCA1/BRCA2 this response was enriched to 80%, and in patients with high inflammatory infiltrate the response rate was 30%, this compares with only a 6% response rate for patients with other defects in DNA damage repair.
The analysis included 36 men with metastatic CRPC (median age, 66.5 years; range: 50-77) who experienced disease progression after at least one line of therapy and had a positive immunogenic signature.
